CASE REPORT

Central diabetes insipidus after syndrome of inappropriate antidiuretic hormone secretion with severe hyponatremia in a patient with Rathke’s cleft cyst

Yudai Hinata1,2, Nobumasa Ohara1, Takeshi Komatsu1,2, Yuki Sakurai1, Yuichiro Yoneoka3, Yasuhiro Seki3, Katsuhiko Akiyama3 and Hirohito Sone2

Abstract:
A 49-year-old man developed severe hyponatremia associated with transient headache and was diagnosed with syndrome of inappropriate antidiuretic hormone secretion (SIADH). Fluid restriction and sodium supplementation corrected the hyponatremia. However, several days later, the patient exhibited hypernatremia with thirst and polyuria. A detailed examination indicated central diabetes insipidus (CDI) with an intrasellar cystic lesion indicative of Rathke’s cleft cyst (RCC). A case of RCC exhibiting headache, hyponatremia, and subsequent hypernatremia has been reported. Our case shows that CDI may appear after SIADH in patients with RCC, especially in those with serum sodium levels that unexpectedly increase rapidly beyond the reference range.

Key words: Arginine vasopressin, central diabetes insipidus, desmopressin, Rathke’s cleft cyst, syndrome of inappropriate antidiuretic hormone secretion, headache

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.6608-20)

Introduction

Rathke’s cleft cysts (RCCs) are benign sellar and/or suprasellar cystic lesions containing mucoid material originating from the remnants of Rathke’s pouch (1, 2). RCCs are usually asymptomatic; however, they present with symptoms when they are large enough to compress surrounding structures or are associated with inflammation extending into adjacent tissues. Common symptoms include headache, visual disturbances, and endocrinopathies.

Arginine vasopressin (AVP) is an antidiuretic hormone produced in the hypothalamus and stored in the posterior lobe of the pituitary gland. AVP acts principally on the renal collecting tubules to increase water reabsorption. Impaired AVP secretion can cause water-electrolyte balance disorders, such as central diabetes insipidus (CDI) and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

CDI is characterized by a large amount of dilute urine due to a deficiency of AVP (3, 4). Clinical manifestations of CDI include thirst, polydipsia, hypotonic polyuria, and hypernatremia. In contrast, SIADH is characterized by water retention and dilutional hyponatremia due to excessive AVP secretion (5). SIADH can cause symptoms of hyponatremia, such as fatigue, appetite loss, nausea, and vomiting.

Both CDI and SIADH are relatively rare manifestations of RCC (6, 7). Furthermore, a case of RCC exhibiting headache, hyponatremia, and subsequent transient hypernatremia has been reported, with combined SIADH and CDI suggested as a possible etiology for the unusual manifestation of a rapid transition from hyponatremia to hypernatremia; however, AVP measurements were not provided (8).

We herein report an unusual case of a patient with RCC who developed headache and SIADH with severe hyponatremia followed by persistent CDI.
A 49-year-old Japanese man was admitted to our hospital in early April 2019 complaining of thirst, polydipsia, and polyuria. His personal and family medical history were unremarkable. The patient developed frontal headache (specifically, a gradually aggravating, throbbing pain in the forehead) in the morning in early March 2019. His headache worsened, and he developed nausea, appetite loss, and fatigue in the evening of the same day. The next morning, the patient visited the Neurosurgery Department of Uonuma Kikan Hospital. He was clear-headed. His height and weight were 169 cm and 56 kg, respectively. His body temperature was 36.7°C. No neurological abnormalities, such as paralysis or numbness, were found. Brain computed tomography (CT) detected no abnormalities in the cerebrum, cerebellum, or brain stem. No hemorrhaging, apoplexy, or calcification were observed in the intrasellar or suprasellar region. The pituitary gland was mildly enlarged (Fig. 1); however, this was not considered a cause of the patient’s headache. His headache was treated with a non-steroidal anti-inflammatory drug (loxoprofen) for seven days. Although his headache improved, the nausea, appetite loss, and fatigue persisted and worsened. Furthermore, the patient experienced repetitive vomiting and revisited the same hospital in mid-March 2019. Because a blood test revealed severe hyponatremia, he was admitted the same day.

At admission, the patient’s body weight, body temperature, blood pressure, and pulse rate were 56 kg, 36.6°C, 129/88 mmHg, and 77 beats/min, respectively. He did not present with symptoms or signs of dehydration, including thirst or dry mouth, and skin. No edema was present in his extremities. The laboratory findings (Table 1) showed low levels of serum sodium (112 mEq/L) and plasma osmolality (Posm; 229 mOsm/kg) and relatively high plasma AVP levels (2.2 pg/mL) and urinary osmolality (Uosm; 514 mOsm/kg). Plasma cortisol levels (15.8 μg/dL) were normal. Chest and abdominal CT revealed abnormalities in the lungs, liver, pancreas, kidneys, and adrenal glands.

The patient received infusion therapy with normal saline; however, his serum sodium level measured 1 h later was reduced (110 mEq/L). He was diagnosed with SIADH. After receiving a 3% saline infusion (Fig. 2), his serum sodium levels increased to approximately 120 mEq/L, and he subsequently took oral sodium chloride (6 g/day). The patient was instructed to restrict his fluid intake to 800 mL/day. His fatigue, appetite loss, nausea, and vomiting resolved along with improved hyponatremia. His serum sodium level measured on day 4 of admission increased to 136 mEq/L. The dose of oral sodium chloride was decreased to 2 g/day, and he was discharged.

The day after discharge, the patient developed thirst, polydipsia, and polyuria, and the next day, he revisited the hospital. A blood test showed a high serum sodium level (147 mEq/L). Oral sodium chloride was discontinued but the hyponatremia persisted; the patient was admitted to the hospital’s department of Endocrinology and Metabolism in early April 2019.

Upon a physical examination, his body weight, temperature, blood pressure, and pulse rate were 53 kg, 36.7°C, 129/96 mmHg, and 82 beats/min, respectively. His mouth was mildly dry. No thyromegaly, heart murmur, chest rale, or peripheral edema were detected. The 24-h urine volume was elevated (4,200 mL/day). Abnormal neurological findings, such as an impaired visual acuity or visual field defect, were not detected. The laboratory findings (Table 1) showed high levels of serum sodium (149 mEq/L) and Posm (298 mOsm/kg) and relatively low levels of plasma AVP (0.9 pg/mL) and Uosm (73 mOsm/kg).

A desmopressin stimulation test showed increased Uosm with reduced urine volume and increased urinary aquaporin-2 levels (Table 2A), indicating CDI. Dynamic function tests for the anterior pituitary showed normal secretion of prolactin, thyroid-stimulating hormone, growth hormone, adrenocorticotropic hormone, luteinizing hormone, and follicle-stimulating hormone (Table 2B, C). A rapid ACTH stimulation test revealed a normal secretory reserve of cortisol (22.1 μg/dL) 60 min after the intravenous administration of tetracosactide acetate (0.25 mg). Serum

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Computed tomography of the head (March 2019). Images in the transverse (A), coronal (B), and sagittal (C) planes.
Table 1. Laboratory Findings.

|                       | 2019 Mid-March | 2019 Early April |
|-----------------------|---------------|------------------|
| **Hematology**        |               |                  |
| Red blood cells (×10⁹/μL) | 516           | 426              | (435–555)       |
| Hemoglobin (g/dL)     | 16.6          | 14.0             | (13.7–16.8)     |
| Hematocrit (%)        | 44.7          | 41.3             | (40.7–50.1)     |
| White blood cells (µL) | 4,300         | 4,200            | (3,300–8,600)   |
| Platelets (×10⁴/µL)   | 12.6          | 17.4             | (15.8–34.8)     |
| **Blood chemistry**   |               |                  |
| Total protein (g/dL)  | 7.0           | 7.4              | (6.6–8.1)       |
| Albumin (g/dL)        | 4.7           | 4.7              | (4.1–5.1)       |
| Uric acid (mg/dL)     | 3.6           | 7.1              | (3.7–7.8)       |
| Urea nitrogen (mg/dL) | 10.7          | 9.5              | (8.0–20.0)      |
| Creatinine (mg/dL)    | 0.65          | 0.68             | (0.65–1.07)     |
| Sodium (mEq/L)        | 112           | 149              | (135–145)       |
| Potassium (mEq/L)     | 4.5           | 3.7              | (3.5–4.8)       |
| Chloride (mEq/L)      | 80            | 109              | (98–108)        |
| C-reactive protein (mg/dL) | 0.36   | 0.02             | (<0.30)         |
| Triglycerides (mg/dL) | 86            | 119              | (50–149)        |
| Casual plasma glucose (mg/dL) | 107           | 96               | (70–139)        |
| Plasma osmolality (mOsm/kg) | 229          | 298              | (275–290)       |
| **Endocrinology**     |               |                  |
| Arginine vasopressin (pg/mL) | 2.2       | 0.9              | *               |
| Thyroid-stimulating hormone (µIU/mL) | N.D. | 1.87             | (0.50–5.00)     |
| Free thyroxine (ng/dL) | N.D.         | 1.10             | (0.90–1.70)     |
| Free triiodothyronine (pg/mL) | 2.96 | (2.30–4.00)     |
| Adrenocorticotropic hormone (pg/mL) | 17.7 | (7.2–63.3)      |
| Cortisol (µg/dL)      | 15.8          | 9.8              | (7.1–19.6)      |
| Dehydroepiandrosterone sulfate (ng/mL) | N.D. | 2.369            | (700–4,950)     |
| Plasma renin activity (ng/mL/h) | 0.5       | 1.4              | (0.1–2.0)       |
| Aldosterone (ng/dL)   | 11.4          | 8.2              | (3.0–15.9)      |
| **Urinary chemistry** |               |                  |
| Urinary osmolality (mOsm/kg) | 514        | 73               | (50–1,300)      |
| Urinary sodium (mEq/L) | 82           | 39               | (88–285)        |
| **Urinalysis**        |               |                  |
| Specific gravity      | N.D.          | 1.001            | (1.005–1.030)   |
| Glucose               | N.D.          | Negative         |
| Protein               | N.D.          | Negative         |
| Occult blood          | N.D.          | Negative         |

Blood samples were taken in the morning with the patient in the supine position.
The reference range for each parameter is shown in parentheses.

*The reference range for the plasma arginine vasopressin level is dependent on the plasma osmolality (5).

N.D.: not determined

levels of insulin-like growth factor-1 (172 ng/mL, reference range: 88-246 ng/mL) and free testosterone (14.6 pg/mL, reference range: 4.7-21.6 pg/mL) were normal.

Magnetic resonance imaging (MRI) of the brain (Fig. 3) showed no abnormalities in the cerebrum, cerebellum, or brain stem but revealed a 9-mm cystic lesion in the midline behind the anterior lobe of the pituitary, with the superior margin of the cyst lying behind the junction point of the infundibular stalk in the sagittal view, without a shift in the infundibular stalk on the coronal view, indicative of RCC. No mechanical compression of the infundibular stalk, hypothalamus, or optic nerve was observed. In terms of the posterior pituitary, the normal high-intensity physiological signal (9) was not detected on T1-weighted imaging.

The patient was started on oral desmopressin at 60 µg/day to treat CDI on day 6 of admission. The dose was adjusted to relieve his thirst, polydipsia, and dilute polyuria, and his symptoms resolved after taking 120 µg/day (twice daily) of desmopressin. Regarding the treatment plan for his RCC, surgical treatment was considered a potentially effective option to prevent future development of additional pituitary defects, but it may not necessarily resolve CDI (1, 2, 10). After the patient was informed of the treatment options, he chose conservative treatment. The patient was continued on
oral desmopressin and discharged at 13 days after admission.

His RCC was closely followed up with MRI; the results obtained in July 2019, October 2019, and March 2020 indicated a decrease in the size of the RCC together with dramatic changes in the signal intensity from the RCC (high to low intensity on T2-weighted imaging at three months after the development of CDI) (Fig. 3).

Laboratory tests performed in October 2020 after a brief discontinuation of desmopressin revealed high levels of sodium (146 mEq/L) and Posm (294 mOsm/kg), and relatively low levels of plasma AVP (0.7 pg/mL) and Uosm (139 mOsm/kg). The patient experienced thirst and polyuria during the tests. He was considered to have persistent CDI, and oral desmopressin (120 μg/day) was continued.

The patient’s clinical course during desmopressin therapy for CDI has been uneventful for more than 1.5 years, with no headache or anterior pituitary dysfunction.

**Discussion**

The differential diagnoses of hyponatremia associated with intracranial disorders include SIADH and cerebral salt-wasting syndrome (CSWS). CSWS is characterized by renal salt loss (natriuresis) leading to hyponatremia and extracellular fluid volume depletion; water and sodium replacement is the mainstay of treatment (11). In contrast, in SIADH, increased renal water reabsorption results in dilutional hyponatremia, and fluid restriction is the treatment of choice. Although it is often difficult to distinguish between SIADH and CSWS, given the clinical and laboratory similarities, the extracellular fluid volume status is the distinguishing feature. Our patient did not experience significant weight loss or symptoms of dehydration when he was severely hyponatremic. Fluid restriction effectively reversed the hyponatremia. Thus, SIADH was the most likely diagnosis. In addition, as non-steroidal anti-inflammatory drugs are known to induce hyponatremia by increasing renal water reabsorption via potentiated effects of AVP as a result of inhibition of renal prostaglandin synthesis (12), the drug the patient received to treat his headache may have exaggerated the hyponatremia.

Several days after resolution of the hyponatremia (Fig. 2), the patient unexpectedly developed hypernatremia with thirst and polyuria and was diagnosed with CDI accompanied by a small intrasellar cystic lesion.

The differential diagnoses of an intrasellar cystic lesion include neoplastic craniopharyngioma, arachnoid cyst, cystic pituitary adenoma, and RCC. Radiological investigation with MRI can be useful for differentiating among these disorders (1, 2, 13-15). Craniopharyngiomas, solid or mixed solid-cystic tumors arising from nests of epithelium along the infundibular stalk, generally occur in the suprasellar region and are often associated with calcium deposits. MRI shows the reticular enhancement of the solid portion. Arachnoid cysts are sacs filled with cerebrospinal fluid covered by arachnoidal cells and collagen, which are indicated by homogeneous hyperintensity signals on T2-weighted MRI that are similar to those of cerebrospinal fluid. Cystic pituitary

![Figure 2](image-url)  
**Figure 2.** Clinical course of the patient. *The day on which the patient developed frontal headache is defined as day 1. Blank columns indicate that the laboratory parameters were not determined. AVP: arginine vasopressin, Posm: plasma osmolality, Uosm: urinary osmolality
adrenomas are often located off the midline and exhibit internal septations. T2-weighted imaging may show the fluid-fluid level or a hypointense rim. RCCs are usually found between the anterior and posterior lobes of the pituitary gland. MRI reveals well-demarcated homogenous lesions of variable intensity that are highly dependent on the cyst contents, and compression of the infundibular stalk and terminate in the posterior pituitary, where AVP is stored in vesicles until it is released into the blood circulation. The loss of magnocellular cells results in CDI. CDI associated with RCC is often accompanied by posterior pituitary inflammation (neurohypophysitis) (16). Furthermore, in a clinical and pathological study of patients with RCC and CDI, the onset of CDI with headache without anterior pituitary dysfunction was suggested to be strongly associated with rupture of the cyst wall adjacent to the posterior pituitary (17). In our case, the onset of headache was associated with an enlarged pituitary detected by CT (Fig. 1). Approximately three weeks later (following the development of CDI after SIADH), MRI revealed a small intrasellar RCC without compression of the infundibular stalk or hypothalamus (Fig. 3D); although the anterior pituitary gland was visible, no T1-weighted high-intensity signal from the posterior pituitary (9) was evident. Within three months, the MRI signal intensity in the RCC changed dramatically from high to low on T2-weighted imaging with the RCC

Table 2. Results of Endocrinological Investigations (April 2019).

| A. Vasopressin stimulation test | Time (min) |
|---------------------------------|------------|
|                                 | 0  | 30  | 60  | 90 | 120 |
| Urinary osmolality (mOsm/kg)    | 134| 145 | 315 | 526| 564 |
| Urinary aquaporin-2 (ng/mL)     | <0.35 | <0.35 | 15.9 | 22.7| 14.9 |
| Urine volume (mL/30 min)        | 350| 100 | 25  | 30 | 25  |
| Plasma osmolality (mOsm/kg)     | 289| N.D.| 291 | N.D.| 291 |

Vasopressin (5 units) was intravenously administered in the morning.
N.D., not determined

| B. Insulin tolerance test | Time (min) |
|--------------------------|------------|
|                         | 0  | 30  | 60  | 90 |
| Plasma glucose (mg/dL)   | 93 | 28  | 67  | 85 |
| Growth hormone (ng/mL)   | 0.48| 0.96 | 4.70 | 2.42 |
| Adrenocorticotropic hormone (pg/mL) | 18.6 | 45.8  | 33.6 | 15.3 |
| Cortisol (μg/dL)         | 11.6| 14.0 | 18.4 | 14.4 |

Regular insulin (5 units) was intravenously administered in the morning.

| C. TRH/LHRH stimulation test | Basal | Peak (time at peak) |
|------------------------------|-------|---------------------|
| Thyroid-stimulating hormone (μIU/mL) | 1.99 | 14.26 (30 min) |
| Prolactin (ng/mL)             | 5.8  | 23.6 (15 min)      |
| Luteinizing hormone (mIU/mL)  | 3.3  | 16.2 (60 min)      |
| Follicle-stimulating hormone (mIU/mL) | 5.4 | 9.9 (90 min)      |

Blood samples were taken before (basal) and at 15, 30, 60, 90, and 120 min after intravenous administration of thyrotropin-releasing hormone (TRH; 500 μg) and luteinizing hormone-releasing hormone (LHRH; 100 μg) in the morning.
The greatest diameter of the patient’s pituitary cystic lesion at different timepoints was 9 mm (April 2019), 7 mm (July 2019), 7 mm (October 2019), and 7 mm (March 2020).

Various patterns of water-electrolyte balance disorders occur after neurosurgery. A typical pattern is a triple-phasic course comprising initial acute CDI, subsequent SIADH, and eventual chronic CDI (18). The initial phase of CDI is due to the inhibition of AVP secretion induced by damage to the infundibular stalk (magnocellular axons). In the second phase, (approximately seven days after surgery), SIADH develops as a result of AVP release from degenerating terminal axons in the posterior pituitary distal to the lesion and from axons proximal to the lesion that undergo ascending degeneration. In the third phase, (approximately 14 days after surgery), CDI reoccurs due to loss of magnocellular cells. This triple-phasic pattern has been observed after head trauma and in patients with RCC complicating hypophysitis (19). If we compare the clinical course of combined SIADH and CDI in our patient with the post-neurosurgery triple-phasic response, increased AVP release followed by decreased secretion of the hormone due to magnocellular cell loss can be seen to be a common underlying phenomenon. However, an important difference is that, in our patient, the initial insult probably resulted from chemical damage to the posterior pi-

Figure 3. Serial magnetic resonance imaging of the pituitary gland. A, T1-weighted sagittal; B, T1-weighted coronal; C, gadolinium-enhanced T1-weighted sagittal; and D, T2-weighted sagittal images.
In conclusion, we encountered a patient with an intrasellar RCC who developed transient headache and SIADH with severe hyponatremia followed by persistent CDI. This case highlights the need for physicians to be aware that CDI may appear after SIADH in patients with RCC, especially in those with serum sodium levels that unexpectedly increase rapidly beyond the reference range.

The authors state that they have no Conflict of Interest (COI).

**Acknowledgement**

The authors thank the clinical laboratory technicians of Uonuma Kikan Hospital for their valuable technical support.

**References**

1. Shin JL, Asa SL, Woodhouse LJ, Smyth HS, Ezzat S. Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke’s cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab 84: 3972-3982, 1999.
2. Nishioka H, Haraoka J, Izawa H, Ikeda Y. Magnetic resonance imaging, clinical manifestations, and management of Rathke’s cleft cyst. Clin Endocrinol (Oxf) 64: 184-188, 2006.
3. Maghnie M. Diabetes insipidus. Horm Res 59 (Suppl 1): 42-54, 2003.
4. Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet 388: 2403-2415, 2016.
5. Spasovski G, Vanholder R, Allolio B, et al.; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 170: G 1-G47, 2014.
6. Iwai H, Ohno Y, Hoshiro M, et al. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and adrenal insufficiency induced by rathke’s cleft cyst: a case report. Endocr J 47: 393-399, 2000.
7. Cohan P, Foulad A, Esposito F, Martin NA, Kelly DF. Symptomatic Rathke’s cleft cysts: a report of 24 cases. J Endocrinol Invest 27: 943-948, 2004.
8. Hsu YJ, Chau T, Yang SS, Tsai WS, Lin SH. Rathke’s cleft cyst presenting with hyponatremia and transient central diabetes insipidus. Acta Neuroscand 107: 382-385, 2003.
9. Kurokawa H, Fujisawa I, Nakano Y, et al. Posterior lobe of the pituitary gland: correlation between signal intensity on T1-weighted MR images and vasopressin concentration. Radiology 207: 79-83, 1998.
10. Barkhoudarian G, Palejwala SK, Anarsi S, et al. Rathke’s cleft cysts: a 6-year experience of surgery vs. observation with comparative volumetric analysis. Pituitary 22: 362-371, 2019.
11. Harrigan MR. Cerebral salt wasting syndrome. Crit Care Clin 17: 125-138, 2001.
12. Llamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 52: 144-153, 2008.
13. Choi SH, Kwon BJ, Na DG, Kim JH, Han MH, Chang KH. Pituitary adenoma, craniopharyngioma, and Rathke cleft cyst involving both intrasellar and suprasellar regions: differentiation using MRI. Clin Radiol 62: 453-462, 2007.
14. Gaddikeri S, Vattoth S, Riley KO, et al. Rathke cleft cyst. MRI criteria for presumptive diagnosis. Neurosciences (Riyadh) 18: 258-263, 2013.
15. Park M, Lee SK, Choi J, et al. Differentiation between cystic pituitary adenomas and rathke cleft cysts: A diagnostic model using MRI. AJNR Am J Neuroradiol 36: 1866-1873, 2015.
16. Hama S, Arita K, Nishisaka T, et al. Changes in the epithelium of Rathke cleft cyst associated with inflammation. J Neurosurg 96: 209-216, 2002.
17. Oishi M, Hayashi Y, Sasagawa Y, Kita D, Tachibana O, Nakada M. Outcome of diabetes insipidus in patients with Rathke’s cleft

| Age (years) | Sex | Hypernatremia | Hypopituitarism | Serum osmolality (mOsm/L) | Plasma AVP (pg/mL) | Treatment (years) | Surgery for RCC | Medication (dopamine for CDI) |
|------------|-----|---------------|----------------|--------------------------|-------------------|-----------------|----------------|-----------------------------|
| 18         | Male| 9             | 22             | 125                      | 346               | N.D.            | 9 days         | Persistent (≥1.5 years)     |
| 40         | Male| 9             | 22             | 112                      | 514               | N.D.            | 19 days        | Persistent (≥1.5 years)     |

**Table 3. Summary of Reported Cases of Rathke’s Cleft Cyst Presenting with Headache, Hypopituitarism, and Subsequent Hypernatremia.**

| Age (years) | Sex | Hypernatremia | Hypopituitarism | Serum osmolality (mOsm/L) | Plasma AVP (pg/mL) | Treatment (years) | Surgery for RCC | Medication (dopamine for CDI) |
|------------|-----|---------------|----------------|--------------------------|-------------------|-----------------|----------------|-----------------------------|
| 18         | Male| 9             | 22             | 125                      | 346               | N.D.            | 9 days         | Persistent (≥1.5 years)     |
| 40         | Male| 9             | 22             | 112                      | 514               | N.D.            | 19 days        | Persistent (≥1.5 years)     |

The authors thank the clinical laboratory technicians of Uonuma Kikan Hospital for their valuable technical support.
cysts. Clin Neurol Neurosurg 167: 141-146, 2018.

18. Hensen J, Henig A, Fahlbusch R, Meyer M, Boehnert M, Buchfelder M. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf) 50: 431-439, 1999.

19. Kim HJ. Triphasic pattern of diabetes insipidus in a pregnant woman with a Rathke’s cleft cyst and hypophysitis. Am J Med Sci 348: 441-443, 2014.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© The Japanese Society of Internal Medicine

Intern Med Advance Publication